DSGN · Nasdaq · CIK 0001807120

Design Therapeutics, Inc.

Design Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Aug 14, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $0 and net income of -$69.8M, according to its XBRL data on EDGAR. Its EDGAR record lists 13 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$0
Net income, FY2025
-$69.8M
Form 4 filings on record, past 12 months
13

Company overview

Legal name (as filed)
Design Therapeutics, Inc.
Ticker
DSGN
SEC Central Index Key (CIK)
0001807120
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
CARLSBAD, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Position in SEC ticker list
#2732 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Design Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023$0FY2024$0FY2025
Net income
-$35.5MFY2021-$63.3MFY2022-$66.9MFY2023-$49.6MFY2024-$69.8MFY2025
DSGN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue———$0$0
Net income-$35.5M-$63.3M-$66.9M-$49.6M-$69.8M
Diluted EPS-$0.77-$1.14-$1.19-$0.88-$1.22
Total assets$390.6M$341.1M$289.6M$252.1M$226.2M
Cash and equivalents$298.6M$26.5M$21.2M$22.6M$16.9M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

DSGN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 9, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 20268-KResults of operations· period Aug 3, 2026Document · Index
Apr 23, 2026DEF 14ADefinitive proxy statement· period Apr 23, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Design Therapeutics, Inc., by form type:

4 ×138-K ×7144 ×3SCHEDULE 13G/A ×310-Q ×3SCHEDULE 13D/A ×3SCHEDULE 13G ×23 ×1DEFA14A ×1DEF 14A ×1ARS ×1S-8 ×110-K ×1
DSGN recent filings
FiledFormWhat it isOriginal
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 20268-KResults of operations· period Aug 3, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 9, 2026Document · Index
Jun 11, 20268-KShareholder vote results· period Jun 9, 2026Document · Index
Jun 9, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 18, 20268-KOther events· period May 18, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 28, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 28, 20268-KResults of operations; Regulation FD disclosure· period Apr 28, 2026Document · Index
Apr 23, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 23, 2026DEF 14ADefinitive proxy statement· period Apr 23, 2026Document · Index
Apr 23, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 1, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 31, 2026Document · Index
Apr 1, 20263Initial statement of beneficial ownership· period Mar 31, 2026Document · Index
Apr 1, 20268-KDirector or officer change· period Mar 31, 2026Document · Index
Mar 11, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Mar 9, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 9, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 9, 20268-KResults of operations· period Mar 9, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 30, 20268-KDirector or officer change· period Jan 29, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Jan 5, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 2, 2026Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Nov 18, 2025144Notice of proposed sale of securitiesDocument · Index
Nov 18, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Nov 14, 2025144Notice of proposed sale of securitiesDocument · Index
Nov 12, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Nov 7, 2025144Notice of proposed sale of securitiesDocument · Index
Nov 5, 202510-QQuarterly report· period Sep 30, 2025Document · Index

Insider filing activity

13 Form 4 filings appear in Design Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001807120 and XBRL company facts. Design Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.